262 related articles for article (PubMed ID: 35314675)
1. Extramedullary disease in multiple myeloma: a systematic literature review.
Bladé J; Beksac M; Caers J; Jurczyszyn A; von Lilienfeld-Toal M; Moreau P; Rasche L; Rosiñol L; Usmani SZ; Zamagni E; Richardson P
Blood Cancer J; 2022 Mar; 12(3):45. PubMed ID: 35314675
[TBL] [Abstract][Full Text] [Related]
2. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Rosiñol L; Beksac M; Zamagni E; Van de Donk NWCJ; Anderson KC; Badros A; Caers J; Cavo M; Dimopoulos MA; Dispenzieri A; Einsele H; Engelhardt M; Fernández de Larrea C; Gahrton G; Gay F; Hájek R; Hungria V; Jurczyszyn A; Kröger N; Kyle RA; Leal da Costa F; Leleu X; Lentzsch S; Mateos MV; Merlini G; Mohty M; Moreau P; Rasche L; Reece D; Sezer O; Sonneveld P; Usmani SZ; Vanderkerken K; Vesole DH; Waage A; Zweegman S; Richardson PG; Bladé J
Br J Haematol; 2021 Aug; 194(3):496-507. PubMed ID: 33724461
[TBL] [Abstract][Full Text] [Related]
3. Extramedullary multiple myeloma.
Weinstock M; Ghobrial IM
Leuk Lymphoma; 2013 Jun; 54(6):1135-41. PubMed ID: 23210572
[TBL] [Abstract][Full Text] [Related]
4. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
[TBL] [Abstract][Full Text] [Related]
5. Genetic Abnormalities in Extramedullary Multiple Myeloma.
McAvera R; Quinn J; Murphy P; Glavey S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511018
[TBL] [Abstract][Full Text] [Related]
6. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
9. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary Plasmacytomas of the Oral Cavity: A Case Report and Review of the Literature.
Bavarian R; Treister NS
J Cancer Allied Spec; 2021; 7(2):e417. PubMed ID: 37197217
[TBL] [Abstract][Full Text] [Related]
11. Diffuse skeletal muscle extramedullary plasmacytomas: a rare case and review of the literature.
Moore RD; Nelson SM; Cecava ND
Skeletal Radiol; 2020 Dec; 49(12):2087-2093. PubMed ID: 32556470
[TBL] [Abstract][Full Text] [Related]
12. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.
Kremer M; Ott G; Nathrath M; Specht K; Stecker K; Alexiou C; Quintanilla-Martinez L; Fend F
J Pathol; 2005 Jan; 205(1):92-101. PubMed ID: 15586381
[TBL] [Abstract][Full Text] [Related]
13. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
[TBL] [Abstract][Full Text] [Related]
14. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Beksac M; Seval GC; Kanellias N; Coriu D; Rosiñol L; Ozet G; Goranova-Marinova V; Unal A; Bila J; Ozsan H; Ivanaj A; Balić LI; Kastritis E; Bladé J; Dimopoulos MA
Haematologica; 2020 Jan; 105(1):201-208. PubMed ID: 31278209
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary Disease in Multiple Myeloma.
Jagosky MH; Usmani SZ
Curr Hematol Malig Rep; 2020 Apr; 15(2):62-71. PubMed ID: 32198576
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Jiménez-Segura R; Granell M; Gironella M; Abella E; García-Guiñón A; Oriol A; Cabezudo E; Clapés V; Soler JA; Escoda L; López-Pardo J; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Bladé J; Rosiñol L;
Eur J Haematol; 2019 May; 102(5):389-394. PubMed ID: 30719772
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary disease in multiple myeloma.
Bansal R; Rakshit S; Kumar S
Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
Tucker SM; Zaihra T
Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
[TBL] [Abstract][Full Text] [Related]
19. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
20. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
